ASSESSMENT THE RESULTS OF SOFOSBUVIR/VELPATASVIR TREATMENT IN CHRONIC HCV - INFECTED PATIENTS AT NATIONAL HOSPITAL FOR TROPICAL DISEASES

Tóm tắt

Objectives: To evaluate the results of treatment of patients with chronic hepatitis C with Sofosbuvir/Velpatasvir regimen and adverse effects of the regimen.

Subjects and methods: A cross sectional descriptive study with follow up 12 weeks after the end of treatment. 46 patients confirmed diagnosis of chronic hepatitis C according to 2016 Guidelines for diagnosis and treatment of hepatitis C virus of Ministry of Health. They received Sofosbuvir 400mg/Velpatasvir 100mg combination once daily for 12 weeks. Patients were followed up six months after the start of therapy. Hepatitis C viral load was assessed at baseline, at week 4 and after 24 weeks following the start of the treatment.

Result: 34 patients without cirrhosis (97.1%) and 10 patients with compensated cirrhosis (90.9%) achieved RVR. A total of 100% of patients without cirrhosis and 90.9% of patients with compensated cirrhosis achieved SVR 12 weeks after the end of therapy. Patients with compensated cirrhosis experienced more adverses events (45.5%) than patients without cirrhosis (8.57%). None of the patients without cirrhosis or with compensated cirrhosis experienced any serious adverse event. A few patients complained about some symtoms such as fatigue (6/46, 13.0%), ichy/rash (2/46, 4.3%), insomnia (2/46, 4.3%), jaundice (1/46, 2.1%) - which appeared after received Sofosbuvir/Velpatasvir therapy. Most certain laboratoty abnormalities were seen in patients with compensated cirrhosis.

Conclusion: The therapy of sofusbuvir/velpatasvir combination daily for 12 weeks is safe and efficacious in hepatitis C patients without cirrhosis or with compensated cirrhosis, irrespective of the genotype.